22 April 2021
: Case report 
Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile
Rare disease
Viviana Abarca-Villaseca1ABCDEF*, Verónica Soto-Arellano2ABCDEFDOI: 10.12659/AJCR.929598
Am J Case Rep 2021; 22:e929598
Table 1. Primary variables.
| 1 year episodic treatment with BPAs | 1 year prophylactic treatment with emicizumab | |
|---|---|---|
| Number of Breakthrough bleeds | 18 | 1 |
| Number of hospitalizations | 2 | 0 |
| Hospitalizations days | 5 | 0 |
| Bleeding episodes diagnosis | ||
| Hematuria | 2 | 0 |
| Hematoma | 7 | 0 |
| Hemarthrosis | 9 | 0 |
| Suppurative otitis | 0 | 1 |
| VAS Score | 5 | 0 |
| Hemophilia Joint Health Score (HJHS) | 39 | 19 |
| Total Haemo-QoL | 128 | 48 |
| Mean Haemo-QoL | 3.6 | 1.37 |
| Standardized Haemo-QoL | 66.4 | 9.3 |
| * Spontaneous bleeding; ** Visual Analogue Scale Pain. Haemo-QoL – Quality of life assessment instrument for children with haemophilia. Author’s elaboration using data from Pediatrics Service, Hospital San Pablo, Coquimbo, Chile. | ||